17‐Oxo‐ DHA Potentiates Macrophage Efferocytosis via Nrf2/ HO ‐1‐Mediated Biosynthesis of Specialized Pro‐Resolving Mediators
IUBMB Life · 2025-09 · 77 (9)
DOI: 10.1002/iub.70057 ↗Kurz gefasst
Fachartikel in der Zeitschrift IUBMB Life, online erschienen am 19.09.2025. Verfasst von Ibrahim Isot und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Medicine, Marmara University, Istanbul, Türkiye. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Docosahexaenoic Acids, Heme Oxygenase-1, Macrophages. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: the National Research Foundation, Republic of Korea, Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.
Abstract (Originalsprache)
Phagocytic engulfment of apoptotic cells, particularly neutrophils by macrophages, known as efferocytosis, is crucial in preventing secondary necrosis and promoting tissue repair. 17‐Oxo‐DHA, an electrophilic metabolite of docosahexaenoic acid (DHA), is generated in macrophages and has been reported to contribute to inflammation resolution by enhancing efferocytosis. However, many gaps remain in our understanding of the pro‐resolving effects of 17‐oxo‐DHA. Our results reveal that 17‐oxo‐DHA augments the efferocytic activity of bone marrow‐derived macrophages (BMDMs) by stimulating the biosynthesis of resolvin D2 (RvD2), one of the prototypic pro‐resolving mediators (SPMs), while reducing the expressions of IL‐6 and TNF‐α. Mechanistically, either gene silencing of Nrf2 or pharmacological inhibition of its target protein HO‐1 suppresses 17‐oxo‐DHA‐induced efferocytosis, decreasing the levels of 15‐LOX, COX‐2, and various SPMs. Notably, treatment of macrophages with SPMs was able to restore 17‐oxo‐DHA‐induced efferocytosis even when HO‐1 activity was suppressed. Thus, our study suggests critical roles of SPMs and the Nrf2/HO‐1 axis in mediating 17‐oxo‐DHA‐induced efferocytosis, which are novel candidate therapeutic targets in non‐resolving inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Medicine, Marmara University, Istanbul, Türkiye.
- Institute of Health Sciences, Marmara University, Istanbul, Türkiye.
- Department of Biochemistry, Faculty of Medicine, Uskudar University, Istanbul, Türkiye.
- Metabolic and Inflammatory Diseases Research Center (METIFLAM), Uskudar University, Istanbul, Türkiye.
- College of Pharmacy, Seoul National University, Seoul, South Korea.
- Genetic and Metabolic Diseases Research and Investigation Center (GEMHAM), Marmara University, Istanbul, Türkiye.
ORCID-Profile: Nesrin Kartal Ozer, Erdi Sozen
Förderung
- the National Research Foundation, Republic of Korea
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
Zitieren
APA
Isot, I., Demir Yangi, D., Demirel-Yalciner, T., Surh, Y. J., Ozer, N. K., & Sozen, E. (2025). 17‐Oxo‐ DHA Potentiates Macrophage Efferocytosis via Nrf2/ HO ‐1‐Mediated Biosynthesis of Specialized Pro‐Resolving Mediators. IUBMB Life, 77(9). https://doi.org/10.1002/iub.70057
Vancouver
Isot I, Demir Yangi D, Demirel-Yalciner T, Surh YJ, Ozer NK, Sozen E. 17‐Oxo‐ DHA Potentiates Macrophage Efferocytosis via Nrf2/ HO ‐1‐Mediated Biosynthesis of Specialized Pro‐Resolving Mediators. IUBMB Life. 2025;77(9). doi:10.1002/iub.70057
BibTeX
@article{Isot2025,
author = {Isot, Ibrahim and Demir Yangi, Doga and Demirel-Yalciner, Tugce and Surh, Young-Joon and Ozer, Nesrin Kartal and Sozen, Erdi},
title = {17‐Oxo‐ DHA Potentiates Macrophage Efferocytosis via Nrf2/ HO ‐1‐Mediated Biosynthesis of Specialized Pro‐Resolving Mediators},
journal = {IUBMB Life},
year = {2025},
volume = {77},
number = {9},
doi = {10.1002/iub.70057}
}
EUVIMED